- Current languageen
Pharmaceuticals - Community Register
Community register of veterinary medicinal products
|Auth. number :||EU/2/11/134|
|Active substance :||Meloxicam|
|ATC:||Anatomical main group: QM - Musculo-skeletal system|
Therapeutic subgroup: QM01 - Antiinflammatory and antirheumatic products
Pharmacological subgroup: QM01A - Antiinflammatory and antirheumatic products, non-steroids
Chemical subgroup: QM01AC - Oxicams
Chemical substance: QM01AC06 - meloxicam
(See WHO ATCvet Index)
Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs.
Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.
Alleviation of mild to moderate post-operative pain and inflammation following surgical procedures in cats, e.g. orthopaedic and soft tissue surgery.
Alleviation of pain and inflammation in acute and chronic musculo-skeletal disorders in cats.
For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.
For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.
For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.
For the relief of post-operative pain following dehorning in calves.
For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.
For the relief of post-operative pain associated with minor soft tissue such as castration.
For use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.
For the relief of pain associated with equine colic.
Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses.
Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses weighing between 500 and 600 kg.
|Marketing Authorisation Holder:||Chanelle Pharmaceuticals Manufacturing Limited
Loughrea, Co. Galway, Ireland
|EPAR and active package presentations|
Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".|
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.
|Close date procedure||Procedure type||EMEA number||Decision||summary publ||decision docs||annex|
|13/12/2011||Centralised - Authorisation||EMEA/V/C/2497||(2011)9445 of 9/12/2011|
|20/08/2012||Centralised - Variation||EMEA/V/C/2497/X/2||(2012)5891 of 16/08/2012|
|12/11/2012||Centralised - Variation||EMEA/V/C/2497/X/1||(2012)8179 of 8/11/2012|
|14/02/2013||Centralised - Variation||EMEA/V/C/2497/WS/344||(2013)913 of 12/02/2013|
|27/09/2013||Centralised - Variation||EMEA/V/C/2497/IB/5|
|Updated with Decision(2014)6276 of 01/09/2014|
|3/09/2014||Centralised - Yearly update||(2014)6276 of 1/09/2014|
|4/12/2015||Centralised - Variation||EMEA/V/C/2497/X/9||(2015)8815 of 2/12/2015|
|8/09/2016||Centralised - Variation||EMEA/V/C/2497/WS/933|
|Updated with Decision(2016)7293 of 09/11/2016|
|28/10/2016||Centralised - Variation||EMEA/V/C/2497/IB/13|
|Updated with Decision(2017)7270 of 24/10/2017|
|11/11/2016||Centralised - Renewal||EMEA/V/C/2497/R/11||(2016)7293 of 9/11/2016|
|26/10/2017||Centralised - Yearly update||(2017)7270 of 24/10/2017|